Plus, news about UTEC, Sellas and Oncomatryx Biopharma:
Otsuka acquires immunology drugs from Cantargia: The agreement will send early-stage CAN10 and preclinical 3G5 to Otsuka for $33 million upfront. Both programs ...
↧